In 2001, Dr. Brian Brink, senior vice president of Anglo American, a massive South African mining conglomerate, was debating how to confront the ravages that extremely high HIV/AIDS rates were taking on Anglo's workforce and overall productivity. According to the firm's best estimates, 21% of Anglo American's workforce was HIV-positive in 2001. Specifically, Dr. Brink was debating the merits of adding a potentially costly antiretroviral component to the existing HIV/AIDS program. Looks at the economic impact of HIV/AIDS on the Anglo workforce; examines the strategic, cost/benefit, and corporate social responsibility issues involved in offering the antiretroviral drug program to workers; contrasts Anglo's programs with its key competitors; and considers the financial, implementation, and political challenges involved in launching the antiretroviral program.